SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.

Original reporting
Published Nov 17, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLS
Bullish
high confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The company claims statistically significant and clinically meaningful overall survival improvement at the pre-specified 80-death analysis, with no new safety signals, and outlines next steps toward FDA discussion and BLA preparations for 1H 2027.

02

Market read

This is a pivotal clinical readout with primary endpoint OS significance and an explicit regulatory timeline, creating a near-term decision point for biotech risk pricing.

03

What to watch

Accelerated filing strategy depends on FDA feedback; trial design details (open-label, BAT composition) and the strength of confirmatory evidence could influence ultimate approval odds.

Relevance 9/10Novelty 9/10Timing: webcast today at 7:45 a.m. ET, ahead of further details and FDA engagement

Background

REGAL is a pivotal randomized Phase 3 trial of galinpepimut-S (GPS) as AML maintenance monotherapy in patients in second or later complete remission who are ineligible for or unable to undergo allogeneic stem cell transplantation.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

SELLAS reports REGAL Phase 3 topline success for galinpepimut-S, with OS hazard ratio 0.59 (p=0.035) and plans FDA meeting plus BLA prep.

Expected impact

Likely upward bias as traders price in improved regulatory odds and a clearer path to an accelerated BLA timeline.

Evidence & confidence

The article discloses primary endpoint achievement with statistically significant OS benefit, plus stated intent to engage FDA and prepare a BLA submission in 1H 2027.

Market effects

Reinforces investor appetite for WT1-targeted immunotherapy and late-stage AML maintenance vaccine strategies.

Primarily US biotech sentiment, with potential spillover to AML-focused peers on perceived competitive validation.

Limited direct global macro impact; mainly affects global AML immunotherapy development expectations.

Counterpoint

Topline OS benefit may not fully de-risk the program until secondary endpoints, subgroup consistency, and detailed safety are reviewed at a medical conference and in the full dataset.

Key entities

  • SELLAS Life Sciences Group, Inc.

    NASDAQ-listed late-stage clinical biopharmaceutical company announcing positive pivotal Phase 3 REGAL results for GPS.

  • Galinpepimut-S (GPS)

    WT1-targeted off-the-shelf immunotherapeutic cancer vaccine evaluated as AML maintenance therapy.

  • REGAL trial

    Phase 3 randomized registrational trial evaluating GPS in AML patients in second or later remission who cannot undergo transplant.

  • U.S. Food and Drug Administration (FDA)

    Regulatory authority SELLAS plans to meet to discuss an accelerated filing strategy and regulatory path forward.

Related articles

$SLSHighAI 9/10

Why is Sellas Life Sciences stock surging today?

Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

$SLSMedAI 8/10

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid